Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 332 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
332 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with previously treated metastatic triple-negative breast cancer (ER/PR ≤10%, HER2–; ECOG 0–1/2) receive sacituzumab govitecan (TROP2-directed SN-38 ADC) plus naxitamab, a humanized anti-GD2 monoclonal antibody, to assess safety and antitumor activity. Excludes prior anti-GD2 or metastatic-setting TROP2 ADC use and active CNS metastases.
ClinicalTrials.gov ID: NCT07011654
TrialFetch AI summary: Adults with advanced/metastatic solid tumors refractory to standard therapy (mCRPC, metastatic breast cancer subtypes including TNBC, HR+/HER2− or HER2-low, HR−/HER2+, NSCLC, CRC, PDAC) receive MBRC-201, an investigational antibody‑drug conjugate targeting a tumor-associated antigen and delivering a likely topoisomerase I inhibitor payload. Requires ECOG 0–2 and measurable disease in expansion/Phase 2; excludes active CNS disease and prior camptothecin‑payload ADCs in later phases.
ClinicalTrials.gov ID: NCT07145255
TrialFetch AI summary: PD-L1–positive metastatic triple-negative breast cancer after one prior line including pembrolizumab (ECOG 0–1; stable brain mets allowed) randomized to sacituzumab govitecan (Trop-2–directed SN-38 ADC) plus nivolumab (PD-1 inhibitor) with or without relatlimab (LAG-3 inhibitor). Compares whether adding LAG-3 blockade to PD-1 with SG improves activity in checkpoint-exposed mTNBC.
ClinicalTrials.gov ID: NCT06963905
TrialFetch AI summary: Adults with metastatic or locally recurrent unresectable triple-negative breast cancer (measurable disease; ECOG 0–2) receive low-dose oral cyclophosphamide plus axatilimab (CSF-1R–blocking antibody to modulate tumor-associated macrophages/myeloid suppression) combined with fixed standard-dose retifanlimab (PD-1 inhibitor). This single-arm dose-finding study focuses on safety/tolerability and identifying recommended doses for the cyclophosphamide/axatilimab additions.
ClinicalTrials.gov ID: NCT06959537
TrialFetch AI summary: Adults with HER2-negative metastatic breast cancer (including triple-negative) and liver-dominant measurable metastases (≤50% liver involvement, limited extrahepatic disease; ECOG 0–1) who have progressed on endocrine therapy + CDK4/6 if HR+ and generally after/unsuitable for a topo-1 payload ADC are randomized to liver-directed induction with melphalan via hepatic arterial infusion using the Melphalan/HDS extracorporeal filtration system (DNA-alkylating/crosslinking agent; aims to boost intrahepatic exposure while limiting systemic toxicity) for up to 2 cycles followed by single-agent chemotherapy (eribulin, vinorelbine, or capecitabine) vs the same physician’s-choice single-agent chemotherapy alone. Primary outcome is hepatic progression-free survival.
ClinicalTrials.gov ID: NCT06875128
TrialFetch AI summary: Single-arm study for adults with de novo stage IV unresectable/metastatic HER2 IHC 3+ breast cancer, ECOG 0–1, no prior systemic/anti-HER2 therapy, and no known CNS metastases. Uses serial tumor-informed ctDNA monitoring to adapt sequential anti-HER2 treatment, including trastuzumab deruxtecan, a HER2-directed antibody–drug conjugate with a topoisomerase I inhibitor payload, with possible escalation/de-escalation, local therapy, and CNS prophylaxis.
ClinicalTrials.gov ID: NCT07459673
TrialFetch AI summary: Adults with previously untreated metastatic PD-L1–positive (CPS ≥10) triple-negative breast cancer and at least two measurable metastatic sites receive high-dose radiotherapy to up to 3 lesions plus first-line pembrolizumab, an anti–PD-1 checkpoint inhibitor, with investigator-selected standard chemotherapy. Chemotherapy options include paclitaxel, nab-paclitaxel, or carboplatin/gemcitabine, with radiotherapy used as experimental immune-augmenting intensification.
ClinicalTrials.gov ID: NCT06492759
TrialFetch AI summary: Open-label single-arm study for adults with ER-positive, HER2-low or HER2-ultralow metastatic/unresectable breast cancer with endocrine resistance after prior endocrine therapy and CDK4/6 inhibitor, no prior metastatic chemotherapy or ADC, and known ESR1 status. Patients receive elacestrant, an oral selective estrogen receptor degrader, plus trastuzumab deruxtecan, a HER2-directed topoisomerase I antibody-drug conjugate.
ClinicalTrials.gov ID: NCT07198724
TrialFetch AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.
ClinicalTrials.gov ID: NCT05269381
TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.
ClinicalTrials.gov ID: NCT06465069